RTS will pay a minimum of $500,000, and Hatch willjoin the company's already established Life Science division, which hassuccessfully served the North American Big Pharma, biotech and leading academicinstitutes for over a decade from its Manchester, U.K., base.
"Hatch is a great strategic fit with RTS; it is akey part of our expansion into our core North American market and will offerthe group greater efficiency as we expand both our offerings and reach in theU.S.," says Gary Walsh, managing director of RTS Life Science. "Hatch adds complementary products and customers and, importantly, bringsHatch's proven product design and manufacturing expertise to the business."
RTS Life Science, a supplier of premium automatedsample management products, biobanking instruments and drug delivery testingequipment, has been co-operating in sales and product development with Hatchfor over a year.
Hatch is a developer and manufacturerof scientific instruments for the pharmaceutical and medical industries,specializing in dissolution testing, spectroscopy and sample preparation, andis located in Fall River, Mass., south of Boston.
Martin Schwalm, the current CEO of Hatch, willcontinue to lead the company, and comments: "This is an incredibly excitingtime for Hatch; our partnership to date with RTS has been mutually beneficial.Joining RTS not only opens up new markets for existing Hatch Science products,but also creates an opportunity to use RTS market insights for the developmentof innovative new products to serve our customers."
